Small Molecules, Big Breakthroughs in Ulcerative Colitis (Online CME/CE Monograph)
Activity Description and Purpose
Since the turn of the century, monoclonal antibodies against tumor necrosis factor α have served as first-line therapies in the treatment of moderately to severely active ulcerative colitis. Although effective in many patients, these medications can lose efficacy over time and prove less useful in those with particular pharmacokinetic profiles. Additionally, these options require regular infusions or subcutaneous injections. These limitations left a gap in the treatment of ulcerative colitis that is beginning to be filled by the approval of newer, orally administered small molecule drugs. The desired results of this activity are to improve clinicians’ familiarity with newly approved and emerging classes (Janus kinase inhibitors, sphingosine-1-phosphate receptor modulators) for the treatment of ulcerative colitis.
This educational activity is intended for gastroenterology clinicians, including physicians, physician assistants, and nurse practitioners, involved in the care of patients with ulcerative colitis.
After completing this activity, participants will be better able to:
- Review the limitations associated with first-line treatments for moderate to severe ulcerative colitis
- Differentiate oral small molecule drugs for the treatment of ulcerative colitis
- Summarize recent clinical trial data for new and emerging oral small molecule drugs for ulcerative colitis
- Identify patients who would be good candidates for treatment with approved or emerging oral small molecule drugs according to clinical trial data
|David T. Rubin, MD (Chair)
Joseph B. Kirsner Professor of Medicine
Chief, Section of Gastroenterology, Hepatology, and Nutrition
University of Chicago Medicine
|Maria T. Abreu, MD
Director, Crohn’s & Colitis Center
Professor of Medicine
Professor of Microbiology and Immunology
Vice Chair for Research, Department of Medicine
Chair, International Organization for the Study of Inflammatory Bowel Disease
University of Miami Miller School of Medicine
|Stephen B. Hanauer, MD
Clifford Joseph Barborka Professor of Medicine
Medical Director, Digestive Disease Center
Feinberg School of Medicine
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Maria T. Abreu, MD, is a consultant for AbbVie Inc, Alimentiv, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Bristol-Myers Squibb Company, Cosmo Pharmaceuticals, Eli Lilly and Company, Gilead, Janssen Global Services, LLC, Prometheus Laboratories, and Takeda Pharmaceuticals USA, Inc; is on the speakers bureau for Alimentiv, Arena Pharmaceuticals, Janssen Global Services, LLC, Microba, Takeda Pharmaceuticals USA, Inc, and UCB SA; and is a contracted researcher for AbbVie Inc, Bristol-Myers Squibb Company, Genentech, Inc, Gilead, Janssen Global Services, LLC, Pfizer Inc, Prometheus Laboratories, and Takeda Pharmaceuticals USA, Inc.
Stephen B. Hanauer, MD, is a consultant for AbbVie Inc, Allergan, Amgen Inc, Arena Pharmaceuticals, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Catalys Pacific, Celgene Corporation, Cosmo Pharmaceuticals, Covance, Eli Lilly and Company, Genentech, Inc, GlaxoSmithKline, Janssen Global Services, LLC, Merck & Co., Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Progenity, Inc, Prometheus Laboratories, Receptos, Salix Pharmaceuticals, Samsung Bioepis, Seres Therapeutics, Sorriso Pharmaceuticals, Inc, Takeda Pharmaceuticals USA, Inc, UCB SA, and VHsquared Ltd; is on the speakers bureau for AbbVie, Bristol-Myers Squibb Company, Janssen Global Services, LLC, Pfizer Inc, and Takeda Pharmaceuticals USA, Inc; is a contracted researcher for AbbVie Inc, Allergan, Amgen Inc, Celgene Corporation, Eli Lilly and Company, Genentech, Inc, GlaxoSmithKline, Janssen Global Services, LLC, Novartis Pharmaceuticals Corporation, Pfizer Inc, Prometheus Laboratories, Receptos, Takeda Pharmaceuticals USA, Inc, and UCB SA; and is on the data and safety monitoring board of Arena Pharmaceuticals, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, and Prometheus Laboratories.
David T. Rubin, MD, is a consultant for AbbVie Inc, Allergan, AltruBio, Arena Pharmaceuticals, Athos Therapeutics, Atlantica, Bellatrix Pharmaceuticals, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Connect Biopharma, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Galen Limited, Genentech, Inc, Gilead, InDex Pharmaceuticals, Ironwood Pharmaceuticals, Inc, Iterative Scopes, Inc, Janssen Global Services, LLC, Materia Prima, Pfizer Inc, Prometheus Laboratories, Reistone Biopharma, Syneos Health, Takeda Pharmaceuticals USA, Inc, and Techlab, Inc; and is a contracted researcher for Takeda Pharmaceuticals USA, Inc.
This activity was peer reviewed. The peer reviewer has no relevant financial relationships.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
ACCME Accreditation Statement
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Interprofessional Joint Accreditation Statement
In support of improving patient care, Amedco is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco LLC designates this activity for a maximum of 1.5 ANCC contact hours.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Arena Pharmaceuticals, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Amedco, or Arena Pharmaceuticals, Inc.
This CME/CE activity is copyrighted to MedEdicus LLC ©2022. All rights reserved. 259.2
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 Participation